Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 247

1.

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

Chen J, Bhatt DL, Dunn ES, Shi C, Caro JJ, Mahoney EM, Gabriel S, Jackson JD, Topol EJ, Cohen DJ.

Value Health. 2009 Sep;12(6):872-9. doi: 10.1111/j.1524-4733.2009.00529.x. Epub 2009 Mar 11.

PMID:
19490556
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.

Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ.

Circulation. 2010 Jan 5;121(1):71-9. doi: 10.1161/CIRCULATIONAHA.109.900704. Epub 2009 Dec 21.

PMID:
20026770
[PubMed - indexed for MEDLINE]
Free Article
3.

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.

PMID:
22853743
[PubMed - indexed for MEDLINE]
4.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
[PubMed - indexed for MEDLINE]
5.

Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS.

J Am Coll Cardiol. 2005 Sep 6;46(5):761-9.

PMID:
16139122
[PubMed - indexed for MEDLINE]
Free Article
6.

Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.

Main C, Palmer S, Griffin S, Jones L, Orton V, Sculpher M, Henderson R, Sudlow C, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(40):iii-iv, xv-xvi, 1-141. Review.

PMID:
15461878
[PubMed - indexed for MEDLINE]
Free Article
7.

Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.

Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R.

Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. Review.

PMID:
15461876
[PubMed - indexed for MEDLINE]
Free Article
8.

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.

Kolm P, Yuan Y, Veledar E, Mehta SR, O'Brien JA, Weintraub WS.

Can J Cardiol. 2007 Nov;23(13):1037-42.

PMID:
17985004
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.

Lyseng-Williamson KA, Plosker GL.

Pharmacoeconomics. 2006;24(7):709-26. Review.

PMID:
16802846
[PubMed - indexed for MEDLINE]
10.

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.

Greenhalgh J, Bagust A, Boland A, Martin Saborido C, Oyee J, Blundell M, Dundar Y, Dickson R, Proudlove C, Fisher M.

Health Technol Assess. 2011 Sep;15(31):1-178. doi: 10.3310/hta15310. Review.

PMID:
21888837
[PubMed - indexed for MEDLINE]
Free Article
11.

Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.

Weintraub WS, Mahoney EM, Lamy A, Culler S, Yuan Y, Caro J, Gabriel S, Yusuf S; CURE Study Investigators.

J Am Coll Cardiol. 2005 Mar 15;45(6):838-45.

PMID:
15766816
[PubMed - indexed for MEDLINE]
Free Article
12.

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.

Logman JF, Heeg BM, Herlitz J, van Hout BA.

Appl Health Econ Health Policy. 2010;8(4):251-65. doi: 10.2165/11535520-000000000-00000.

PMID:
20578780
[PubMed - indexed for MEDLINE]
13.

The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.

Lindgren P, Stenestrand U, Malmberg K, J├Ânsson B.

Clin Ther. 2005 Jan;27(1):100-10.

PMID:
15763611
[PubMed - indexed for MEDLINE]
14.

A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN.

Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID:
19843493
[PubMed - indexed for MEDLINE]
15.

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Bhatt DL, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee.

Am Heart J. 2004 Aug;148(2):263-8.

PMID:
15308995
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.

Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW.

Am J Cardiol. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. Epub 2012 Jan 3.

PMID:
22221944
[PubMed - indexed for MEDLINE]
17.

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.

Schleinitz MD, Weiss JP, Owens DK.

Am J Med. 2004 Jun 15;116(12):797-806.

PMID:
15178495
[PubMed - indexed for MEDLINE]
18.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.

PMID:
12050341
[PubMed - indexed for MEDLINE]
Free Article
19.

Economic evaluation of clopidogrel plus aspirin for secondary prevention of cardiovascular events in Canada for patients with established cardiovascular disease: Results from the CHARISMA trial.

Chen J, Shi C, Mahoney EM, Dunn ES, Rinfret S, Caro JJ, O'Brien J, El-Hadi W, Bhatt DL, Topol EJ, Cohen DJ.

Can J Cardiol. 2011 Mar-Apr;27(2):222-31. doi: 10.1016/j.cjca.2010.12.021.

PMID:
21459271
[PubMed - indexed for MEDLINE]
20.

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.

Berger K, Hessel F, Kreuzer J, Smala A, Diener HC.

Curr Med Res Opin. 2008 Jan;24(1):267-74.

PMID:
18053318
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk